CMS are rare neuromuscular disorders that cause fatigable weakness of skeletal muscles. Credit: Gerd Altmann from Pixabay.

Catalyst Pharmaceuticals has reported top-line data from the Phase III CMS-001 clinical trial of Firdapse (amifampridine phosphate) as a symptomatic treatment of congenital myasthenic syndromes (CMS).

Firdapse holds approval to treat adults with Lambert-Eaton Myasthenic Syndrome (LEMS). It is being developed for the treatment of other neuromuscular and neurological diseases, including CMS.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CMS are rare neuromuscular disorders with a range of more than 50 genetic defects. Patients experience fatigable weakness of skeletal muscles.

CMS-001 is a double-blind, placebo-controlled trial involving a total of 20 patients aged two years and above enrolled over nearly four years. It assessed the safety and efficacy of the drug.

The trial failed to meet the primary endpoint of subject global impression (SGI) and the secondary endpoint of muscle function measure (MFM) across all tested CMS subtypes.

Catalyst said that individual improvements were observed in certain patient sub-groups.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Catalyst Pharmaceuticals chairman and CEO Patrick McEnany said: “While we are disappointed that this trial did not reach its primary or secondary endpoints in the evaluated CMS patient subtypes, we are pleased with the new valuable clinical information that these results will provide to the medical and scientific communities as we work to develop FDA-approved treatment options for patients with this disease.”

The company is set to discuss the trial data with the US Food and Drug Administration (FDA) by the end of the year. The discussion will also involve possibilities to seek approval for amifampridine phosphate in the symptomatic treatment of a select subset of genetic subtypes of CMS.

Catalyst added that patient enrolment is ongoing in the drug’s trial for the treatment of anti-MuSK antibody positive myasthenia gravis (MuSK-MG). Top-line results from this study are expected to be available in the first half of next year.

Data from the spinal muscular atrophy (SMA) type-3 proof of concept study is expected during the same period.